RxDoctor Payments Data

Wesam Alhejily, MD

Interventional Cardiology · Victorville, CANPI 1437412814

Payments from drug & device makers

$1,235in general payments, 2019–2025

Across 34 payments — averaging $36.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$916
  • Medtronic$166
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$69
  • Johnson & Johnson$39
  • Boehringer Ingelheim$28
  • Convatec Inc.$16

What the payments were for

  • Travel & lodging$42334%
  • Food & beverage$81166%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,235 in reported general payments places this provider in the 15th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$231,496
Medicare patients
988
Services billed
2,945

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban106$107,698
EntrestoSacubitril/Valsartan101$81,223
JardianceEmpagliflozin20$17,858
FarxigaDapagliflozin Propanediol11$14,553
Nifedipine ErNifedipine73$1,236
Ezetimibe29$681
Metoprolol Succinate70$572
Atorvastatin Calcium58$412
Isosorbide Mononitrate ErIsosorbide Mononitrate34$394
FenofibrateFenofibrate Nanocrystallized16$393
Carvedilol60$296
Potassium Chloride19$265
Rosuvastatin Calcium27$241
ClopidogrelClopidogrel Bisulfate32$211
Amiodarone Hcl30$158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$28$17,85820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Victorville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →